New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents
- 1 July 1996
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 40 (7), 1604-1609
- https://doi.org/10.1128/aac.40.7.1604
Abstract
A new model for the evaluation of antifungal compounds against oropharyngeal and gastrointestinal mucosal colonization by Candida albicans was developed. To simulate the immune deficiency observed in AIDS patients, mice were depleted of CD4+ T lymphocytes by the injection of either GK1.5 hybridoma cells or purified anti-CD4+ T lymphocytes by the injection of either GK1.5 hybridoma cells or purified anti-CD4+ monoclonal antibody derived from GK1.5 hybridoma cells in tissue culture. Fluorescence-activated cell sorter analysis of splenic lymphocytes confirmed the elimination of the CD4+ T-cell population. Gentamicin, a broad-spectrum, nonabsorbable aminoglycoside antibiotic, was given via the drinking water to reduce the normal gastrointestinal microflora, allowing less competition for colonization of the gastrointestinal tract by the C. albicans isolates. Mice were challenged by gavage and swabbing their oral mucosae with a pure culture of C. albicans. Gentamicin was withdrawn 3 days postchallenge, and antifungal compounds were administered via the drinking water ad libitum at concentrations ranging from 25 to 400 micrograms/ml. L-693989, a water-soluble phosphorylated cyclic lipopeptide prodrug of pneumocandin Bo, and L-733560, a semisynthetic derivative of pneumocandin Bo, are inhibitors of 1,3-beta-D-glucan synthesis that exhibit potent in vivo anti-Candida spp. and anti-Pneumocystis carinii activities. The efficacies of L-693989, L-733560, fluconazole, ketoconazole, and nystatin were evaluated in this new oropharyngeal and gastrointestinal model of mucosal colonization. L-693989, L-733560, fluconazole, and ketoconazole showed superior efficacies in reducing the numbers of C. albicans CFU per gram of feces and the numbers of oral CFU relative to those in sham-treated controls in this model, while nystatin was moderately effective in reducing oral and fecal colonization by C. albicans in this model.Keywords
This publication has 21 references indexed in Scilit:
- Unexplained Opportunistic Infections and CD4+ T-Lymphocytopenia without HIV Infection -- An Investigation of Cases in the United StatesNew England Journal of Medicine, 1993
- REDUCED CD4+ T CELLS AND SEVERE ORAL CANDIDIASIS IN ABSENCE OF HIV INFECTIONThe Lancet, 1989
- Effect of Thermal Injury and Immunosuppression on the Dissemination of Candida albicans from the Mouse Gastrointestinal TractJournal of Burn Care & Rehabilitation, 1989
- Treatment of Infections Associated with Human Immunodeficiency VirusNew England Journal of Medicine, 1988
- Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicansAntimicrobial Agents and Chemotherapy, 1987
- Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1984
- Oral Candidiasis: Pathogenesis and Host DefenseClinical Infectious Diseases, 1984
- Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual MenNew England Journal of Medicine, 1981
- Fungemia in the immunocompromised hostThe American Journal of Medicine, 1981
- The prevalence and intra-oral distribution of Candida albicans in manArchives of Oral Biology, 1980